Endocrine Abstracts

Background: Dapagliflozin was the first SGLT2 inhibitor licensed in UK to improve glycaemic control in type 2 diabetes. Whilst it has not been studied for use in combination with GLP1 agonists the modes of action of the two therapies suggest they would be a logical therapeutic combination. We aimed to evaluate clinical experience with this regimen.Methods: Observational retrospective data was collected from electronic patient records (SCI–diabetes) ...

Background: Dapagliflozin was the first SGLT2 inhibitor licensed in UK to improve glycaemic control in type 2 diabetes. The study aimed to assess impact of dapagliflozin on glucose, weight and BP and identify factors predictive of glycaemic response in a large cohort.Methods: Observational retrospective data collected on all patients prescribed dapagliflozin across primary and secondary care in two Scottish health board areas. HbA1c, weight, BP and conco...